Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
IJMS | Free Full-Text | HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer | HTML
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - The Lancet Oncology
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
Debbrah clinical trial | MEDSIR
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
DESTINY-Breast01 - Capsule Summary Slidesets - Breast Cancer - 2019 SABCS - Oncology - Clinical Care Options
IJMS | Free Full-Text | Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors | HTML
![iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (](https://assets.posterview.com/SABCS/2019/1/Jpg/f/OT1-07-01.jpg "iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (")
iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (
ds8201 - Twitter Search / Twitter
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study - The Lancet Oncology
Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram
Debbrah clinical trial | MEDSIR
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors - Yin - 2021 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
Clinical Trials for Metastatic HER2-positive Breast Cancer
NCT03329690 (Clinical Trial/ DS-8201a - trastuzumab deruxtecan) » ADC Review
NCT02564900 (Clinical Trials/ DS-8201a) » ADC Review
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape - ESMO Open
Clinical Trials for Metastatic HER2-positive Breast Cancer
DS-8201a for Breast Cancer Clinical Trial | Power
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond | SpringerLink
